Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026
Syndax (Nasdaq: SNDX) will report its fourth quarter and full year 2025 financial results and provide a business update on Thursday, February 26, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Syndax (Nasdaq: SNDX) will report its fourth quarter and full year 2025 financial results and provide a business update on Thursday, February 26, 2026. Management will host a conference call and live audio webcast at 4:30 p.m. ET the same day.
Investors can join via the live webcast or dial in using the provided conference numbers and Conference ID. A replay will be posted on the Investors section of the company website approximately 24 hours after the call and will remain available for 90 days.
Details
News Market Reaction – SNDX
On Feb 19, the day this news came out, SNDX closed 1.88% above the previous close.
Data tracked by StockTitan Argus for the Feb 19 session.
Key Figures
- Earnings date
- February 26, 2026
- Scheduled Q4 and full-year 2025 results release
- Event time
- 4:30 p.m. ET
- Start time for conference call and webcast
- Conference ID
- Syndax4Q25
- Identifier for accessing the earnings call
- Domestic dial-in
- 800-590-8290
- U.S. toll-free number for the call
- International dial-in
- 240-690-8800
- International access number for the call
- Replay availability
- 24 hours after
- Replay posted about 24 hours post-call
- Replay duration
- 90 days
- Replay available on website for 90 days
- 52-week range
- $8.58–$22.73
- Pre-news 52-week low and high for SNDX
Historical Context
-
Announcement of CEO fireside chat at Guggenheim biotech summit.
-
Inducement option grants to new employees under 2023 plan.
-
Preliminary 4Q25 and 2025 revenues plus cash and trial plans.
-
Managed Access Program expanding Revuforj reach outside U.S.
-
Planned CEO presentation at J.P. Morgan Healthcare Conference.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its fourth quarter and full year 2025 financial results and provide a business update on Thursday, February 26, 2026.
In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Thursday, February 26, 2026.
The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following:
Conference ID: Syndax4Q25
Domestic Dial-in Number: 800-590-8290
International Dial-in Number: 240-690-8800
Live webcast: https://sndx-4q25.open-exchange.net/
For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website at www.syndax.com approximately 24 hours after the conference call and will be available for 90 days following the call.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X and LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.